Expression of 'drugable' tyrosine kinase receptors in malignant peripheral nerve sheath tumour: Potential molecular therapeutic targets for a chemoresistant cancer

Histopathology

Volumn 59, Issue 1, 2011, Pages 156-159

  Torres, Keila E ^a   Liu, Jun ^a   Young, Eric ^a   Huang, Kai Lieh ^a,b   Ghadimi, Markus ^a   Lusby, Kristelle ^a   Lazar, Alexander J ^a,b   Lev, Dina ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SOMATOMEDIN; STEM CELL FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

CANCER RESISTANCE; HUMAN; LETTER; NEUROFIBROMA; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

DRUG RESISTANCE, NEOPLASM; HUMANS; NERVE SHEATH NEOPLASMS; NEUROFIBROMA, PLEXIFORM; PROTEIN ARRAY ANALYSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 79960455910     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03867.x     Document Type: Letter

References (8)

1. Zou C, Smith KD, Liu J et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann. Surg. 2009; 249; 1014-1022.
2. Zou CY, Smith KD, Zhu QS et al. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol. Cancer Ther. 2009; 8; 1157-1168.
3. Traxler P. Tyrosine kinases as targets in cancer therapy-successes and failures. Exp. Opin. Ther. Targets 2003; 7; 215-234.
4. Mellinghoff IK, Sawyers CL. The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics 2002; 3; 603-623.
5. Katz D, Lazar A, Lev D. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Exp. Rev. Mol. Med. 2009; 11; e30.
6. Holtkamp N, Malzer E, Zietsch J et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro. Oncol. 2008; 10; 946-957.
7. Albritton KH, Rankin C, Coffin CM et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J. Clin. Oncol 2006 ASCO Ann. Meeting Proc. 2006; 24(Part I); 9518.
8. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316; 1039-1043.